119 related articles for article (PubMed ID: 3358904)
1. Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line.
Supino R; Mariani M; Capranico G; Colombo A; Parmiani G
Br J Cancer; 1988 Feb; 57(2):142-6. PubMed ID: 3358904
[TBL] [Abstract][Full Text] [Related]
2. Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline.
Broggini M; Grandi M; Ubezio P; Geroni C; Giuliani FC; D'Incalci M
Biochem Pharmacol; 1988 Dec; 37(23):4423-31. PubMed ID: 3202888
[TBL] [Abstract][Full Text] [Related]
3. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
[TBL] [Abstract][Full Text] [Related]
4. Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration.
Bellamy WT; Dorr RT; Dalton WS; Alberts DS
Cancer Res; 1988 Nov; 48(22):6360-4. PubMed ID: 3180055
[TBL] [Abstract][Full Text] [Related]
5. Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicin.
Supino R; Mariani M; Prosperi E; Parmiani G
Cancer Chemother Pharmacol; 1988; 21(3):251-4. PubMed ID: 3359560
[TBL] [Abstract][Full Text] [Related]
6. In vivo characterization of a doxorubicin resistant B16 melanoma cell line.
Formelli F; Rossi C; Supino R; Parmiani G
Br J Cancer; 1986 Aug; 54(2):223-33. PubMed ID: 3741758
[TBL] [Abstract][Full Text] [Related]
7. Drug sensitivity of heat-resistant mouse B16 melanoma variants.
Kroll DJ; Borgert CJ; Wiedmann TW; Rowe TC
Radiat Res; 1990 Oct; 124(1):15-21. PubMed ID: 2236492
[TBL] [Abstract][Full Text] [Related]
8. Verapamil potentiation of doxorubicin resistance development in B16 melanoma cells both in vitro and in vivo.
Formelli F; Supino R; Cleris L; Mariani M
Br J Cancer; 1988 Apr; 57(4):343-7. PubMed ID: 3390370
[TBL] [Abstract][Full Text] [Related]
9. In vitro selection and characterization of a bleomycin-resistant subline of B16 melanoma.
Zuckerman JE; Raffin TA; Brown JM; Newman RA; Etiz BB; Sikic BI
Cancer Res; 1986 Apr; 46(4 Pt 1):1748-53. PubMed ID: 2418953
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin resistance circumvention by verapamil in B16 melanoma cells.
Mariani M; Prosperi E; Colombo A; Supino R
Anticancer Res; 1989; 9(1):29-32. PubMed ID: 2705752
[TBL] [Abstract][Full Text] [Related]
11. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.
Sinha BK; Haim N; Dusre L; Kerrigan D; Pommier Y
Cancer Res; 1988 Sep; 48(18):5096-100. PubMed ID: 2842045
[TBL] [Abstract][Full Text] [Related]
12. DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells.
Capolongo L; Belvedere G; D'Incalci M
Cancer Chemother Pharmacol; 1990; 25(6):430-4. PubMed ID: 2311171
[TBL] [Abstract][Full Text] [Related]
13. The influence of Na+,K(+)-pump blockade on doxorubicin-mediated cytotoxicity and DNA strand breakage in human tumor cells.
Lawrence TS; Davis MA
Cancer Chemother Pharmacol; 1990; 26(3):163-7. PubMed ID: 2162743
[TBL] [Abstract][Full Text] [Related]
14. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes.
Ling YH; Priebe W; Yang LY; Burke TG; Pommier Y; Perez-Soler R
Cancer Res; 1993 Apr; 53(7):1583-9. PubMed ID: 8453627
[TBL] [Abstract][Full Text] [Related]
15. Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.
Ganapathi R; Schmidt H; Grabowski D; Melia M; Ratliff N
Br J Cancer; 1988 Sep; 58(3):335-40. PubMed ID: 3179186
[TBL] [Abstract][Full Text] [Related]
16. Formation, resealing and persistence of DNA breaks produced by 4-demethoxydaunorubicin in P388 leukemia cells.
Capranico G; Tinelli S; Zunino F
Chem Biol Interact; 1989; 72(1-2):113-23. PubMed ID: 2555070
[TBL] [Abstract][Full Text] [Related]
17. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
Politi PM; Sinha BK
Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
[TBL] [Abstract][Full Text] [Related]
18. Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors.
Formelli F; Cleris L; Carsana R
Cancer Chemother Pharmacol; 1988; 21(4):329-36. PubMed ID: 3370742
[TBL] [Abstract][Full Text] [Related]
19. Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933.
Alaoui Jamali MA; Yin MB; Mazzoni A; Bankusli I; Rustum YM
Cancer Chemother Pharmacol; 1989; 25(2):77-83. PubMed ID: 2598402
[TBL] [Abstract][Full Text] [Related]
20. Dipyridamole modulates multidrug resistance and intracellular as well as nuclear levels of doxorubicin in B16 melanoma cells.
Damle BD; Sridhar R; Desai PB
Int J Cancer; 1994 Jan; 56(1):113-8. PubMed ID: 8262666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
